☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
Attralus
Attralus’ 124I-Evuzamitide (AT-01) Gains the US FDA’s Breakthrough Therapy Designation for the Diagnosis of Cardiac Amyloidosis
August 5, 2024
Attralus Published Results from 2 Studies for 124I-Evuzamitide in the Journal of American College of Cardiology
November 8, 2023
Gregory Bell, CMO at Attralus Shares Insights from its License Agreement with Ossianix to Use Ossianix’s Brain Shuttle Technology
May 30, 2023
Attralus Entered into Option and License Agreement with Ossianix to Deliver AT-04 for the Treatment of Neurodegenerative Disorders
November 18, 2022
Jonathan Wall, Co-founder & Interim CSO at Attralus Share Insights from its New Data Presented across its Amyloidosis Portfolio at...
October 17, 2022
Load more...
Back to Home
Modal title
×
Modal body text goes here.